Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19481335rdf:typepubmed:Citationlld:pubmed
pubmed-article:19481335lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0018418lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0039286lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0285590lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C1554217lld:lifeskim
pubmed-article:19481335lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:19481335pubmed:issue2lld:pubmed
pubmed-article:19481335pubmed:dateCreated2010-2-1lld:pubmed
pubmed-article:19481335pubmed:abstractTextBicalutamide monotherapy is a valuable option for prostate cancer (PCa) patients who wish to avoid the consequences of androgen deprivation; however, this treatment induces gynaecomastia and mastalgia in most patients. Tamoxifen is safe and effective in preventing breast events induced by bicalutamide monotherapy without affecting antitumor activity, but possible interference between bicalutamide and tamoxifen remains a matter of concern. To reduce the exposure to tamoxifen, we considered the putative advantages of weekly administration.lld:pubmed
pubmed-article:19481335pubmed:languageenglld:pubmed
pubmed-article:19481335pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:citationSubsetIMlld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19481335pubmed:statusMEDLINElld:pubmed
pubmed-article:19481335pubmed:monthFeblld:pubmed
pubmed-article:19481335pubmed:issn1873-7560lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:UsIuIulld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:AragonaFrance...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:MartoranaGius...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:BoccardoFranc...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:Di...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:RubagottiAles...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:GallucciMiche...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:CortelliniPie...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:LapiniAlberto...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:ContiGiarioGlld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:BedognettiDav...lld:pubmed
pubmed-article:19481335pubmed:authorpubmed-author:CancliniLucaLlld:pubmed
pubmed-article:19481335pubmed:copyrightInfoCopyright 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.lld:pubmed
pubmed-article:19481335pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19481335pubmed:volume57lld:pubmed
pubmed-article:19481335pubmed:ownerNLMlld:pubmed
pubmed-article:19481335pubmed:authorsCompleteYlld:pubmed
pubmed-article:19481335pubmed:pagination238-45lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:meshHeadingpubmed-meshheading:19481335...lld:pubmed
pubmed-article:19481335pubmed:year2010lld:pubmed
pubmed-article:19481335pubmed:articleTitleAn open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.lld:pubmed
pubmed-article:19481335pubmed:affiliationUniversity of Genoa, Genoa, Italy.lld:pubmed
pubmed-article:19481335pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19481335pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:19481335pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19481335pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19481335pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:19481335pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed